162 related articles for article (PubMed ID: 18488155)
1. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.
Saitoh A; Narita M; Watanabe N; Tochiki N; Satoh N; Takizawa J; Furukawa T; Toba K; Aizawa Y; Shinada S; Takahashi M
Med Oncol; 2008; 25(2):137-47. PubMed ID: 18488155
[TBL] [Abstract][Full Text] [Related]
2. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
3. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
[TBL] [Abstract][Full Text] [Related]
4. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
Knight A; Mackinnon S; Lowdell MW
Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
[TBL] [Abstract][Full Text] [Related]
5. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
Zhou J; Kang N; Cui L; Ba D; He W
Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
7. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP
Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838
[TBL] [Abstract][Full Text] [Related]
8. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells.
von Lilienfeld-Toal M; Nattermann J; Feldmann G; Sievers E; Frank S; Strehl J; Schmidt-Wolf IG
Clin Exp Immunol; 2006 Jun; 144(3):528-33. PubMed ID: 16734623
[TBL] [Abstract][Full Text] [Related]
9. Anti-lymphoma effect of gammadelta T cells.
Kunzmann V; Wilhelm M
Leuk Lymphoma; 2005 May; 46(5):671-80. PubMed ID: 16019504
[TBL] [Abstract][Full Text] [Related]
10. Systemic β-Adrenergic Receptor Activation Augments the
Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
Front Immunol; 2019; 10():3082. PubMed ID: 32038628
[TBL] [Abstract][Full Text] [Related]
11. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
12. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
[TBL] [Abstract][Full Text] [Related]
15. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
17.
Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
Front Immunol; 2019; 10():1792. PubMed ID: 31428094
[TBL] [Abstract][Full Text] [Related]
18. γδ T cells in immunotherapies for B-cell malignancies.
Rimailho L; Faria C; Domagala M; Laurent C; Bezombes C; Poupot M
Front Immunol; 2023; 14():1200003. PubMed ID: 37426670
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells.
Saito A; Narita M; Yokoyama A; Watanabe N; Tochiki N; Satoh N; Takizawa J; Furukawa T; Toba K; Fuse I; Aizawa Y; Shinada S; Takahashi M
J Clin Exp Hematop; 2007 Nov; 47(2):61-72. PubMed ID: 18040145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]